Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Genetically engineered hematopoietic cells such as hematopoietic stem cells having one or more genetically edited genes of lineage-specific cell-surface proteins and therapeutic uses thereof, either alone or in combination with immune therapy that targets the lineage-specific cell-surface proteins.

Disclosed is a method for producing a stem cell with enhanced efficacy, a stem cell produced thereby, and a method for treating a disease using the same.

According to the present invention, sizes of stem cells may be reduced and proliferation ability, differentiation potency, migration ability, and angiogenic potential of stem cells may be significantly enhanced by applying a culturing method provided herein. Thus the present invention may be usefully applied to development of therapeutic agents using stem cells.

Disclosed is a method for producing a stem cell with enhanced efficacy, a stem cell produced thereby, and a method for treating a disease using the same.

According to the present invention, sizes of stem cells may be reduced and proliferation ability, differentiation potency, migration ability, and angiogenic potential of stem cells may be significantly enhanced by applying a culturing method provided herein. Thus the present invention may be usefully applied to development of therapeutic agents using stem cells.

Provided are a vesicle and the use thereof. The vesicle is an induced vesicle, and the sources thereof include stem cells or somatic cells, and the possessed markers include Syntaxin 4. Compared with an exosome in mesenchymal stem cells, the vesicle can specifically express Syntaxin 4 and can be used to distinguish characteristic markers of MSC-derived vesicles and exosomes. The vesicle can play a procoagulant effect in vitro, can improve the bleeding tendency of mice with hemophilia after in vivo injection, and can be used for the treatment of improving the bleeding tendency of hemophilia. In addition, the vesicle can be expelled through the skin and hair.

Provided are a vesicle and the use thereof. The vesicle is an induced vesicle, and the sources thereof include stem cells or somatic cells, and the possessed markers include Syntaxin 4. Compared with an exosome in mesenchymal stem cells, the vesicle can specifically express Syntaxin 4 and can be used to distinguish characteristic markers of MSC-derived vesicles and exosomes. The vesicle can play a procoagulant effect in vitro, can improve the bleeding tendency of mice with hemophilia after in vivo injection, and can be used for the treatment of improving the bleeding tendency of hemophilia. In addition, the vesicle can be expelled through the skin and hair.

The present invention relates to a method or a composition for treating neurodegenerative diseases, and particularly, the present invention relates to a method for treating neurodegenerative diseases of the cerebellum, comprising administering a composition comprising stem cells as an active ingredient to a patient having a neurodegenerative disease of the cerebellum, or to a composition for treating neurodegenerative diseases of the cerebellum comprising mesenchymal stem cells as an active ingredient. The treatment method or the treatment composition using mesenchymal stem cells, according to the present invention, has remarkable effects in reducing neuroinflammation, inhibiting M1 microglia, activating M2 microglia, inhibiting apoptosis of Purkinje cells, inhibiting death of neurons, improving motor ability, and the like, and therefore may be effectively utilized in alleviating and treating neurodegenerative diseases including cerebellar ataxia and multiple system atrophy.

The present invention relates to a method or a composition for treating neurodegenerative diseases, and particularly, the present invention relates to a method for treating neurodegenerative diseases of the cerebellum, comprising administering a composition comprising stem cells as an active ingredient to a patient having a neurodegenerative disease of the cerebellum, or to a composition for treating neurodegenerative diseases of the cerebellum comprising mesenchymal stem cells as an active ingredient. The treatment method or the treatment composition using mesenchymal stem cells, according to the present invention, has remarkable effects in reducing neuroinflammation, inhibiting M1 microglia, activating M2 microglia, inhibiting apoptosis of Purkinje cells, inhibiting death of neurons, improving motor ability, and the like, and therefore may be effectively utilized in alleviating and treating neurodegenerative diseases including cerebellar ataxia and multiple system atrophy.

The present invention relates to a composition, comprising: IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α, for promoting immunomodulatory activity and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory activity and inflammation-modulating ability by using same. When treated with IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α according to the present invention, stem cells are induced to increase IFN-γ inhibition, inducible costimulatory ligand (ICOSL) expression, indoleamine 2,3-dioxygenase (IDO) expression, and Galectin 1 expression, and thus can find various applications in a variety of immune disease treatment fields using stem cells.

The present invention relates to a composition, comprising: IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α, for promoting immunomodulatory activity and inflammation-modulating ability of stem cells, and a method for preparing stem cells having improved immunomodulatory activity and inflammation-modulating ability by using same. When treated with IL-1β and vitamin B6; or IL-1β, vitamin B6, and IFN-α according to the present invention, stem cells are induced to increase IFN-γ inhibition, inducible costimulatory ligand (ICOSL) expression, indoleamine 2,3-dioxygenase (IDO) expression, and Galectin 1 expression, and thus can find various applications in a variety of immune disease treatment fields using stem cells.